This study also demonstrates that EGA-treatment effectively lowered IFNα expression to LL-37, an amphipathic peptide implicated in autoimmunity (1–4), to deliver nucleic acids to endo-lysosomes, suggesting that EGA might have the potential in regulating certain autoimmune disorders, including SLE. This evidence concerns the gene IFNA2 and systemic lupus erythematosus.